Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evogene (EVGN) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Evogene (EVGN) over the last 13 years, with Q3 2025 value amounting to $125000.0.

  • Evogene's Capital Expenditures rose 34642.86% to $125000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $580000.0, marking a year-over-year increase of 11481.48%. This contributed to the annual value of $120000.0 for FY2024, which is 8471.34% down from last year.
  • Per Evogene's latest filing, its Capital Expenditures stood at $125000.0 for Q3 2025, which was up 34642.86% from $11000.0 recorded in Q2 2025.
  • Evogene's Capital Expenditures' 5-year high stood at $442000.0 during Q1 2022, with a 5-year trough of -$305000.0 in Q2 2022.
  • For the 5-year period, Evogene's Capital Expenditures averaged around $36157.9, with its median value being $28000.0 (2024).
  • Per our database at Business Quant, Evogene's Capital Expenditures plummeted by 20975.61% in 2021 and then skyrocketed by 34642.86% in 2025.
  • Over the past 5 years, Evogene's Capital Expenditures (Quarter) stood at $260000.0 in 2021, then tumbled by 176.54% to -$199000.0 in 2022, then soared by 143.22% to $86000.0 in 2023, then surged by 274.42% to $322000.0 in 2024, then tumbled by 61.18% to $125000.0 in 2025.
  • Its last three reported values are $125000.0 in Q3 2025, $11000.0 for Q2 2025, and $122000.0 during Q1 2025.